ABVC BioPharma (ABVC) Stock Statistics & Valuation Metrics

ABVC BioPharma has a market cap or net worth of $51.62M. The enterprise value is $9.96M.

ABVC BioPharma has 16,981,592 shares outstanding. The number of shares has decreased by -2.65% in one year.

ABVC BioPharma’s return on equity (ROE) is -4.00 and return on invested capital (ROIC) is -116.92%.

The current PE Ratio of ABVC BioPharma is ―. ABVC BioPharma’s PEG ratio is ―.

In the last 12 months, ABVC BioPharma had revenue of 509.59K and earned -4.90M in profits. Earnings per share was -0.42.

In the last 12 months, operating cash flow was -1.76M and capital expenditures 0.00, giving a free cash flow of -1.76M billion.

ABVC BioPharma pays an annual dividend of ―, resulting in a dividend yield of ―

ABVC BioPharma upcoming earnings date is Nov 17, 2025, Before Open (Confirmed).

ABVC BioPharma as a current ratio of 0.33, with Debt / Equity ratio of 22.61%

In the past 12 months, ABVC BioPharma has paid -111.00K in taxes.

ABVC BioPharma EV to EBITDA ratio is -2.26, with an EV/FCF ratio of -5.44.

ABVC BioPharma has $453.46K in cash and marketable securities with $1.59M in debt, giving a net cash position of $1.13M billion.

Gross margin is 70.80%, with operating margin of -923.29%, and net profit margin of -962.15%.

The average price target for ABVC BioPharma is ―, which is 11.43% higher than the current price. The consensus rating is ―